Ranpirnase was originally discovered by scientists at [[TamirBio]], a [[biotechnology]] company (formerly Alfacell Corporation), where it was tested in preclinical assays<ref>Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent.Cell Tissue Kinet. 1988 May;21(3):169-82. {{PMID|3224365}}</ref> and in [[clinical trial]]s under the name ''Pannon'' or ''Onconase'', respectively. The [[mechanism of action]] of ranpirnase tumor-selective cytotoxicity has been attributed to the [[RNA interference]] pathway, potentially through cleaving [[siRNA]] molecules;<ref name="zhao">{{Cite journal
